AU Patent

AU2026202287A1 — Methods of treating fabry patients having renal impairment

Assigned to Amicus Therapeutics Inc · Expires 2026-04-16 · 0y expired

What this patent protects

The present invention relates to migalastat or a salt thereof for use in the treatment of Fabry disease, preferably in a patient having renal impairment.

USPTO Abstract

The present invention relates to migalastat or a salt thereof for use in the treatment of Fabry disease, preferably in a patient having renal impairment.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

Patent Metadata

Patent number: AU2026202287A1
Jurisdiction: AU
Classification: —
Expires: 2026-04-16
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.